Using ALDH inhibition to improve immune response in ovarian cancer
ALDH Inhibition as Modulator of Tumor Immunobiology
This study is looking at how a special enzyme in ovarian cancer can be blocked to help kill cancer cells and boost the immune system, with the hope of finding new treatments that could make a difference for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Magee-Women's Res Inst and Foundation NIH-funded |
| Lab location | 1 site (Pittsburgh, UNITED STATES) |
| Project ID | NIH-10834276 on NIH RePORTER |
What this research studies
This research investigates the role of aldehyde dehydrogenase-1A (ALDH1A) enzymes in ovarian cancer, particularly how inhibiting these enzymes can affect cancer cells and immune cells. The study aims to explore a novel inhibitor that may induce cancer cell death while simultaneously enhancing the immune response against tumors. By understanding the mechanisms involved, the research seeks to develop new therapeutic strategies that could improve patient outcomes in ovarian cancer. Patients may benefit from potential new treatments that leverage the immune system to fight cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer, particularly those with advanced or treatment-resistant disease.
Not a fit: Patients with non-ovarian cancers or those who are not eligible for experimental treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for ovarian cancer patients.
How similar studies have performed: Other research has shown promise in using immune modulation strategies in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Pittsburgh, UNITED STATES
- Magee-Women's Res Inst and Foundation — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Buckanovich, Ronald J — Magee-Women's Res Inst and Foundation
- Study coordinator: Buckanovich, Ronald J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.